Principal component analysis of PiB distribution in Parkinson and Alzheimer diseases

Neurology

Volumn 81, Issue 6, 2013, Pages 520-527

  Campbell, Meghan C ^a   Markham, Joanne ^a   Flores, Hubert ^a   Hartlein, Johanna M ^a   Goate, Alison M ^a   Cairns, Nigel J ^a   Videen, Tom O ^a   Perlmutter, Joel S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; PITTSBURGH COMPOUND B;

AGED; ALZHEIMER DISEASE; ARTICLE; BINDING AFFINITY; CLINICAL DEMENTIA RATING; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; IMAGE ANALYSIS; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; PRINCIPAL COMPONENT ANALYSIS; PROTEIN BINDING; THIAZOLES;

EID: 84884569192     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31829e6f94     Document Type: Article

References (32)

1. Hurtig HI, Trojanowski JQ, Galvin J, et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000;54:1916-1921.
2. Kotzbauer PT, Cairns NJ, Campbell MC, et al. Pathologic accumulation of alpha-synuclein and A beta in Parkinson disease patients with dementia. Arch Neurol 2012;69: 1326-1331.
3. Braak H, Muller CM, Rub U, et al. Pathology associated with sporadic Parkinson's disease: where does it end? J Neural Transm Suppl 2006;89-97.
4. Ballard C, Ziabreva I, Perry R, et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 2006;67:1931-1934.
5. Compta Y, Parkkinen L, O'Sullivan SS, et al. Lewy-and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain 2011;134:1493-1505.
6. Sabbagh MN, Adler CH, Lahti TJ, et al. Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis Assoc Disord 2009;23:295-297.
7. Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Postmortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008;131:1630-1645.
8. Edison P, Rowe CC, Rinne JO, et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008;79:1331-1338.
9. Maetzler W, Reimold M, Liepelt I, et al. [11C]PIB binding in Parkinson's disease dementia. Neuroimage 2008;39: 1027-1033.
10. Maetzler W, Liepelt I, Reimold M, et al. Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis 2009;34:107-112.
11. Gomperts SN, Rentz DM, Moran E, et al. Imaging amyloid deposition in Lewy body diseases. Neurology 2008; 71:903-910.
12. Foster ER, Campbell MC, Burack MA, et al. Amyloid imaging of Lewy body-associated disorders. Mov Disord 2010;25:2516-2523.
13. Gomperts SN, Locascio JJ, Rentz DM, et al. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology 2013;80:85-91.
14. Fripp J, Bourgeat P, Acosta O, et al. Appearance modeling of 11C PiB PET images: characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging. Neuroimage 2008;43:430-439.
15. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43: 2412-2414.
16. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55: 181-184.
17. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 2005;65:1863-1872.
18. Mintun MA, LaRossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006;67:446-452.
19. Morris JC, Roe CM, Grant EA, et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 2009;66:1469-1475.
20. Resnick SM, Sojkova J, Zhou Y, et al. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology 2010;74:807-815.
21. Mathis CA, Wang YM,HoltDP,HuangGF, DebnathML, Klunk WE. Synthesis and evaluation of C-11-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003;46:2740-2754.
22. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996;16:834-840.
23. Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloidbeta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010;67:122-131.
24. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's diseaserelated pathology. Cell Tissue Res 2004;318:121-134.
25. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-1124.
26. Braak H, Braak E. Neuropathological stageing of Alzheimerrelated changes. Acta Neuropathol 1991;82:239-259.
27. Lashley T, Holton JL, Gray E, et al. Cortical alpha-synuclein load is associated with amyloid-beta plaque burden in a subset of Parkinson's disease patients. Acta Neuropathol 2008;115: 417-425.
28. Irwin DJ, White MT, Toledo JB, et al. Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 2012;72:587-598.
29. Price JL, Morris JC. Tangles and plaques in nondemented aging and preclinical Alzheimer's disease. Ann Neurol 1999; 45:358-368.
30. Kikis EA, Gidalevitz T, Morimoto RI. Protein homeostasis in models of aging and age-related conformational disease. Adv Exp Med Biol 2010;694:138-159.
31. Deleidi M, Maetzler W. Protein clearance mechanisms of alpha-synuclein and amyloid-beta in Lewy body disorders. Int J Alzheimers Dis 2012;2012:391438.
32. Jellinger KA, Wenning GK, Seppi K. Predictors of survival in dementia with Lewy bodies and Parkinson dementia. Neurodegener Dis 2007;4:428-430.